Abstract
Oral fingolimod (Gilenya) is a sphingosine-1-phosphate-receptor modulator that prevents the egress of lymphocytes from lymph nodes. Fingolimod reduces relapses and delays disability progression in patients with relapsing forms of multiple sclerosis (MS). We report a patient with MS who developed asystole and sustained bradycardia 21 hours after the first dose of fingolimod.
MeSH terms
-
Administration, Oral
-
Antipsychotic Agents / adverse effects
-
Bradycardia / chemically induced
-
Electrocardiography
-
Fingolimod Hydrochloride
-
Heart Arrest / chemically induced*
-
Heart Arrest / diagnosis
-
Humans
-
Immunosuppressive Agents / administration & dosage
-
Immunosuppressive Agents / adverse effects*
-
Male
-
Multiple Sclerosis / drug therapy*
-
Propylene Glycols / administration & dosage
-
Propylene Glycols / adverse effects*
-
Risperidone / adverse effects
-
Sphingosine / administration & dosage
-
Sphingosine / adverse effects
-
Sphingosine / analogs & derivatives*
-
Time Factors
-
Young Adult
Substances
-
Antipsychotic Agents
-
Immunosuppressive Agents
-
Propylene Glycols
-
Fingolimod Hydrochloride
-
Risperidone
-
Sphingosine